Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST [gastrointestinal stromal tumours] with a high risk of recurrence

Trial Profile

Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST [gastrointestinal stromal tumours] with a high risk of recurrence

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2015 Results published in the Journal of Clinical Oncology
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 01 Feb 2012 The US FDA has approved a labelling update to include 36 months' imatinib treatment post-surgery in patients with KIT-positive gastrointestinal stromal tumours, based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top